|
|||||
|
|
|
|
|
|
 |
|
 |
|
|
|||||||||||
| Track 1 | Phase III trial of everolimus versus placebo in patients with mRCC progressing on sunitinib and/or sorafenib |  |
|||||||||
| Track 2 | Everolimus and improved disease stabilization | |
|||||||||
| Track 3 | Similarities in efficacy and toxicity of everolimus and temsirolimus | |
|||||||||
| Track 4 | AVOREN trial: Interferon alpha-2a with or without bevacizumab as first-line therapy for mRCC | |
|||||||||
| Track 5 | Clinical trials of bevacizumab combined with interferon |
|
|||||||||
| Track 6 | Efficacy of front-line sunitinib versus bevacizumab/interferon | |
|||||||||
| Track 7 | Etiology of hyperglycemia secondary to mTOR inhibitors | |
|||||||||
| Track 8 | Hypercholesterolemia and hyperlipidemia associated with mTOR inhibitors | |
|||||||||
| Track 9 | Toxicities in a Phase I trial combining sunitinib and temsirolimus | |
|||||||||
| Track 10 | Toxicities observed with the combination of sunitinib and bevacizumab | |
|||||||||
| Track 11 | Emerging trials comparing front-line combinations of novel biologics in mRCC | |
|||||||||
| Track 12 | Updated efficacy data from a clinical trial comparing sunitinib versus interferon for mRCC | |
|||||||||
| Track 13 | ASSURE trial: Sunitinib versus sorafenib versus placebo in patients with high-risk tumors | |
|||||||||
| Track 14 | Management of side effects secondary to TKIs | |
|||||||||
| Track 15 | Clinical trial evaluating optimal duration of adjuvant sorafenib | |
|||||||||
| Track 16 | Impact of bevacizumab on wound healing | |
|||||||||
| Track 17 | Defining adverse prognostic factors | |
|||||||||
| Track 18 | Completion of clinical trials in uncommon tumors | |
|||||||||
| Track 19 | Incidence and treatment of nonclear cell RCC | |
|||||||||
| Track 20 | Limitations of RECIST criteria to predict survival benefit with biologic agents | |
|||||||||
|
|||||||||||
| Track 1 | Everolimus versus placebo after progression on sunitinib and/or sorafenib in mRCC | |
|||||||||
| Track 2 | Toxicity and efficacy data with everolimus after sunitinib and/or sorafenib | |
|||||||||
| Track 3 | Tolerability and efficacy of the mTOR inhibitors temsirolimus and everolimus | |
|||||||||
| Track 4 | Efficacy of sunitinib compared to interferon in mRCC | |
|||||||||
| Track 5 | Tolerability of TKIs in elderly patients | |
|||||||||
| Track 6 | Updated AVOREN trial efficacy and toxicity data |
|
|||||||||
| Track 7 | Clinical trial of bevacizumab with or without erlotinib in mRCC | |
|||||||||
| Track 8 | Bevacizumab monotherapy in the treatment of mRCC | |
|||||||||
| Track 9 | Pitfalls of indirect comparisons of clinical trial data | |
|||||||||
| Track 10 | Identifying surrogates to predict benefit from targeted therapies | |
|||||||||
| Track 11 | In vitro data demonstrating a relationship between hypoxia-inducible factor (HIF) and tumor
sensitivity to sunitinib |
|
|||||||||
| Track 12 | Antitumor effect of sunitinib | |
|||||||||
| Track 13 | Correlation between HIF levels and rate of tumor regression in patients treated with sunitinib | |
|||||||||
| Track 14 | Elevated HIF levels predict poor prognosis | |
|||||||||
| Track 15 | Potential nonsynonymous single nucleotide polymorphisms (nsSNPs) associated with sunitinib-associated toxicity | |
|||||||||
| Track 16 | Clinical trials combining bevacizumab and TKIs | |
|||||||||
| Track 17 | Active clinical trials comparing monotherapy versus combination therapy in mRCC | |
|||||||||
 |
Terms of Use and General Disclaimer | Privacy Policy Copyright © 2008 Research To Practice. All Rights Reserved. |
 |
